News | January 16, 2013

Biopsy Capability Being Developed for Gamma Medica’s LumaGEM

Molecular breast imaging company Gamma Medica, Inc. is expanding the capabilities of its LumaGEM Molecular Breast Imaging (MBI) System with a biopsy accessory. Gamma Medica’s technology clearly lights up tumors, even those obscured by dense breast tissue. This new LumaGUIDE hardware and software package, currently a work-in-progress, will allow physicians to precisely identify and biopsy suspicious lesions. The new procedure is quick (about half the time of an MRI-guided biopsy), easy-to-use, and streamlined.

“Gamma Medica’s MBI-guided biopsy accessory will allow physicians to sample areas of abnormal radiotracer uptake that may be poorly visualized on other imaging modalities,” said Jim Calandra, CEO. “This new tool will allow physicians to take full advantage of MBI’s detection capabilities and enable them to guide radiological interventions including biopsy, marker placement, and surgical guidance.”
 
The new LumaGUIDE accessory will offer several advantages, including:

  • Depth calculation is automatically done by software: no manual calculation required. There’s a straight hub-to hub insertion of the biopsy tool.
  • The use of Tc-99m Sestamibi as a tracer allows the physician to biopsy multiple or bilateral lesions with minimal patient preparation.
  • After biopsy, samples can be scanned, providing immediate confirmation that the target lesion was accurately sampled.

“LumaGEM’s 91 percent sensitivity and 93 percent specificity allows physicians to detect cancer earlier and reduce unnecessary mastectomies, especially in the approximately 40% of women who have dense breasts, where fibrous tissue blocks the view,” said James Hugg, Ph.D., CTO. “LumaGUIDETM includes a 3rd CZT-based camera to provide precise Cartesian targeting capabilities in the x, y and z dimensions for biopsy and surgical interventions.” 

For more information: www.gammamedica.com

 

 

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Siemens Healthineers Introduces Mammomat Revelation Mammography System for Improved Biopsy Workflow
Technology | Mammography | December 11, 2017
Siemens Healthineers unveiled the new Mammomat Revelation premium mammography platform at the 2017 Radiological Society...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Overlay Init